TechDoctor Presents Results of Wearable Data Research at American Society of Clinical Oncology 'ASCO 2026'

TechDoctor, Inc. (CEO: Kazunori Minato; headquarters: Chuo-ku, Tokyo; hereinafter 'TechDoctor') has had the results of its analytical collaboration—conducted with ExaWizards Inc.—on a wearable data utilization study for early-stage breast cancer patients, led by Kansai Medical University Hospital and Daiichi Sankyo Co., Ltd., presented as a poster at the 2026 ASCO Annual Meeting, hosted by the American Society of Clinical Oncology (ASCO), one of the world’s largest oncology conferences.

This study is a prospective observational trial targeting early-stage breast cancer patients undergoing neoadjuvant chemotherapy. It continuously collects real-world data from daily life by leveraging physical activity, sleep, and heart rate data obtained from Google Fitbit (hereinafter 'Fitbit') and electronic patient-reported outcomes (ePRO).

TechDoctor was responsible for providing the data collection infrastructure for wearable data and ePRO, as well as conducting exploratory data analysis using machine learning, thereby supporting the execution of the study.

## Background and Study Overview

Neoadjuvant chemotherapy for early-stage breast cancer is typically administered on an outpatient basis, making it essential to continuously monitor patients’ conditions throughout treatment.

In recent years, interest has grown in data collection using wearable devices and electronic patient-reported outcomes (ePRO), with increasing efforts to apply real-world data collected during daily life to medical care and research.

This study is a prospective observational study targeting early-stage breast cancer patients undergoing neoadjuvant chemotherapy. It continuously collects daily-life data—such as physical activity, sleep, and heart rate—from wearable devices, along with patient-reported data via ePRO, and conducts analyses focusing on the relationship between the two.

## Study Overview

Study Name:

"A Prospective Observational Study to Evaluate Physical Activity Using Wearable Devices in Early-Stage Breast Cancer Patients Initiating Neoadjuvant Chemotherapy (TRACK-BC)"

Principal Investigator:

Dr. Yuichiro Kikawa, Professor of Breast Surgery, Comprehensive Medical Center, Kansai Medical University (affiliated with the University Hospital at the time of study initiation)

Presenter:

Dr. Nobuhiro Shibata, Lecturer, Department of Clinical Oncology, Kansai Medical University Hospital

TechDoctor’s Responsibilities:

- Provision of infrastructure for collecting wearable data and ePRO
- Data management and analytical support
- Conducting exploratory data analysis

## Social Significance and Future Outlook

Cancer drug therapies are increasingly administered on an outpatient basis, allowing patients to continue their daily lives during treatment. However, continuously monitoring adverse events and changes in health status remains a significant challenge.

Recently, interest in data collection and analysis using wearable devices and ePRO has increased, with growing initiatives to apply objective real-world data to medical care and research. These efforts are expected to serve as a new approach for more comprehensively understanding patients’ conditions.

TechDoctor will continue to aim for the realization of new healthcare and medical solutions based on daily-life data through research and analysis utilizing wearable data.

Detailed analytical results from this study are scheduled to be reported through future academic presentations and peer-reviewed publications.

## Conference Presentation Overview

Conference Name: 2026 ASCO Annual Meeting

Presentation Dates: May 29 – June 2, 2026
Format: In-person and online (McCormick Place, Chicago, IL & Online)

Presentation Format: Poster presentation

Official Website: https://www.asco.org/annual-meeting

## About TechDoctor, Inc.

TechDoctor, Inc. operates under the vision of 'Creating an era where data improves well-being,' developing and implementing 'digital biomarkers*'—indicators that derive health insights from everyday sensing data collected via wearable devices and other sources. The company collaborates with healthcare, pharmaceutical, food-related companies, and research institutions to realize AI-driven medical solutions based on data.

CEO: Kazunori Minato
Headquarters: 4F, Kyobashi Edogrand, 2-2-1 Kyobashi, Chuo-ku, Tokyo
Founded: June 21, 2019
Business Activities: Development and operation of the digital biomarker development platform 'SelfBase,' provision of digital healthcare solutions
URL: https://www.technology-doctor.com/

* Digital Biomarkers
Digital biomarkers are indicators that continuously and objectively assess the presence or absence of disease, changes in condition, or treatment efficacy based on everyday physiological data collected from smartphones or wearable devices. Unlike traditional biomarkers, which are temporary 'point-in-time' measurements taken in medical settings, digital biomarkers capture continuous 'longitudinal' data from daily life. Based on metrics such as movement, sleep, and heart rate, they are expected to support early disease detection, treatment monitoring, and even serve as novel endpoints in drug development. Development has been advancing globally since around 2019, with growing domestic attention in Japan.